NorthView Acquisition Corporation
NVACW
NASDAQ Global Market0.11
USD
-0.01
- -
CIK
0001859807
ISIN
US66718N1110
CUSIP
66718N111
Return %
Stock
S&P500
1Y
148.31
18.46
3Y
249.21
64.72
5Y
-55.10
72.79
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ben Chung-Bin Hwang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 207 West 25th Street New York City NY United States of America 10001
- IPO Date
- Jan 24, 2022
- CIK
- 0001859807
- Website
- northviewac.com
- Similar Companies
- Business
- NorthView Acquisition Corporation (NVACW) operates as a blank-check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, particularly targeting healthcare innovation sectors. Incorporated in 2021 and headquartered at 207 West 25th Street, 9th Floor, New York, New York, the company functions without significant independent operations prior to completing a transaction; its primary activities encompass identifying and evaluating potential targets, conducting due diligence, negotiating merger agreements, and securing shareholder approvals for business combinations. As a subsidiary of NorthView Sponsor I, LLC, it raises capital through public offerings of units comprising common stock, warrants, and rights to facilitate acquisitions, with warrants (NVACW) providing holders the right to purchase shares upon deal completion or exercise conditions. The company's core offerings center on its SPAC structure, which serves as an alternative investment vehicle for public market investors seeking exposure to private operating businesses via de-SPAC transactions; it does not manufacture products or provide ongoing services but instead offers redeemable shares, public warrants (NVACW), and rights traded on OTC markets post-initial listing on Nasdaq. Geographically, NorthView targets opportunities primarily in the United States, with a strategic emphasis on healthcare innovators developing technologies like biosensors or digital health solutions. In a pivotal development, NorthView completed a reverse merger with Profusa, Inc., a digital health company specializing in tissue-integrated biosensors, on July 11, 2025, following shareholder approval on July 9, 2025; the combined entity operates as Profusa, Inc., with common stock trading on Nasdaq under PFSA since July 14, 2025, while NVACW warrants continue on OTC. This transaction, initially announced in November 2022 at a pro forma equity value of up to $416 million, underwent multiple extensions—including to June 22, 2025—and amendments, such as revised earnout milestones and a non-redemption agreement with investors I-Bankers Securities and Dawson James Securities to preserve cash amid redemptions. Profusa raised $9 million via a secured convertible promissory note from an institutional investor, part of a $20 million facility, to fund operations and working capital post-merger, reducing net debt to $14 million as of October 31, 2025, alongside manufacturing build-out for its Lumee Oxygen Platform targeting early 2026 EU revenue. NorthView faced a Nasdaq delisting notice prior to closing due to deadline pressures but transitioned successfully through the deal, marking its strategic shift from blank-check entity to supporting Profusa's commercialization of biosensor platforms for tissue oxygen monitoring in peripheral artery disease, chronic wounds, and reconstructive surgery.